Multiplexed MRM based protein quantification of putative prognostic biomarkers for chronic kidney disease progression in plasma
Current diagnostic measures for Chronic Kidney Disease (CKD) include detection of reduced estimated glomerular filtration rate (eGFR) and albuminuria, which have suboptimal accuracies in predicting disease progression. The disease complexity and heterogeneity underscore the need for multiplex quantification of different markers. The goal of this study was to determine the association of six previously reported CKD associated plasma proteins [B2M (Beta 2 microglobulin) SERPINF1 (Pigment epithelium derived factor) AMBP (Protein AMBP) LYZ (Lysozyme C) HBB (Hemoglobin subunit beta) and IGHA1 (Immunoglobulin heavy constant alpha 1) as measured in a multiplex format, with kidney function, and outcome. Antibody free, multiple reaction monitoring mass spectrometry (MRM) assays were developed, characterized for their analytical performance, and used for the analysis of 72 plasma samples from a patient cohort with longitudinal follow up. The MRM significantly correlated (Rho 0.5 0.9) with results from respective ELISA. Five proteins [AMBP, B2M, LYZ, HBB and SERPINF1] were significantly associated with eGFR, with the three former also associated with unfavorable outcome. The combination of these markers provided stronger associations with outcome (p 0.0001) compared to individual markers. Collectively, our study describes a multiplex assay for absolute quantification and verification analysis of previously described putative CKD prognostic markers, laying the groundwork for further use in prospective validation studies.
Scientific Reports